Combination chemotherapy with adriamycin-cyclophosphamide for advanced ovarian carcinoma

L. M. Parker, C. T. Griffiths, R. A. Yankee, G. P. Canellos, R. Gelman, R. C. Knapp, Carol M Richman, J. S. Tobias, R. S. Weiner, E. Frei IIIrd

Research output: Contribution to journalArticlepeer-review

36 Scopus citations


Combination chemotherapy with Adriamycin-cyclophosphamide was employed after surgical treatment in 60 women with Stage III-IV ovarian adenocarcinoma. Of 53 evaluable patients, objective response was noted in 34 of 41 (83%) without prior cytotoxic therapy but in only two of 12 (17%) who had failed a single alkylating agent or radiotherapy (P<.005). Complete response was confirmed by a negative biopsy at the site(s) of prior disease in 12 patients. Eleven of the 12 biopsy-confirmed complete responses were achieved in patients without pretreatment palpable tumor. Twenty-four out of 41 patients with palpable masses responded but only one was confirmed as complete. Confirmed complete responses had a median duration of 24 months, whereas the median duration of all other responses was only seven months. The median survival for patients in whom Adriamycin-cyclophosphamide was the initial chemotherapy was 24 months. The median survival in patients with palpable tumor exceeds that of historical controls matched for age, tumor cell type, and grade (P=.05); the median survival for the confirmed complete responders has not been reached. The toxicity of this regimen was acceptable at doses of Adriamycin and cyclophosphamide of 45 mg and 500 mg/M 2 body surface area, respectively. Extensive excision of tumor followed by effective combination chemotherapy offers the best current approach toward improved patient survival in advanced ovarian cancer.

Original languageEnglish (US)
Pages (from-to)669-674
Number of pages6
Issue number4
StatePublished - 1980
Externally publishedYes

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Combination chemotherapy with adriamycin-cyclophosphamide for advanced ovarian carcinoma'. Together they form a unique fingerprint.

Cite this